115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H.; Figura, N.; Ladbury, C.; Keit, E. R.; Chew, J.; Fregonese, B.; Silverman, E. A.; Hajj, C.; Shah, G.; Kambhampati, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Drug‐resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation
    Meeting Abstract

    Montoya, S.; Bourcie, J.; Sondhi, A.; Jahn, J.; Alencar, A.; Abdel-Wahab, O.; Taylor, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 inhibitors in ibrutinib resistance mantle cell lymphoma
    Meeting Abstract

    Kersy, O.; Salmon‐Divon, M.; Gomes da Silva, M.; Moita, F.; Cabecadas, J.; Trněný, M.; Basood, M.; Abdel-Wahab, O.; Klener, P.; Shpilberg, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • 3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant
    Meeting Abstract

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long term outcome of peripheral T cell lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network
    Meeting Abstract

    Civallero, M.; Advani, R.; Horwitz, S.; Manni, M.; Cabrera, M. E.; Vose, J.; Spina, M.; Hits, F.; Nagler, A.; Montoto, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: Outcomes by baseline histology
    Meeting Abstract

    Mehta‐Shah, N.; Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter‐Brown, L.; Izutsu, K.; Waters, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of subcutaneous epcoritamab versus axi‐cel in R/R DLBCL CAR T‐naive and CAR T‐eligible patients: An indirect comparison
    Meeting Abstract

    Thieblemont, C.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Salles, G.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas
    Meeting Abstract

    Fregonese, B.; Imber, B.; Lee, J.; Zhang, Z.; Toumbacaris, N.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save